Boehringer Ingelheim International Gmbh

Orexo Ab

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Vetmedica Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Klaus Klinder

Cornelia Dorner-Ciossek

Henri Doods

Christoph Hoenke

Roland Pfau

Peter Nickolaus

Kirsten Arndt

Raimund Kuelzer

Dennis Fiegen

Pascale Pouzet

Rolf Goeggel

Thomas Fox

Marcus Kostka

Norbert Hauel

Klaus Fuchs

Klaus Bornemann

Dirk Stenkamp

Horst Dollinger

Ralf Anderskewitz

Henning Priepke

Domnic Martyres

Sandra Handschuh

Juergen Mack

Bernd Beck

Frank Sams-Dodd

Dagmar Kugler

Guenter Trummlitz

Stefan Peters

Niklas Heine

Christian Eickmeier

Frank Himmelsbach

Hans Briem

Stephan Georg Mueller

Herbert Nar

Alexander Pautsch

Benjamin Pelcman

Werner Stransky

Angelo Ceci

Thomas Weiser

Edgars Suna

Stefan Hoerer

Edward S Lazer

Robert Roenn

Clara K Miao

Dimitrijs Lubriks

Ursula Mueller-Vieira

Karin Winter

Katja Fechteler

Cornelia Dorner-Clossek

Kelly Allers

Markus Kostka

The present invention relates to novel 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamides of formula A and pharmaceutically acceptable salts thereof, wherein Rto Rare as defined herein. The invention also relates to processes for the preparation of these compound, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions in which inhibition of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme may be beneficial.

2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament

Dihydrothienopyrimidinesulphoxides of formula 1 wherein X is SO or SO, Ris H or C-alkyl, Ris H or an organic group as disclosed herein, and Ris an optionally substituted, mono- or bicyclic, unsaturated, partially saturated or saturated heterocycle or an optionally substituted, mono- or bicyclic heteroaryl, and the pharmacologically acceptable salts thereof, as well as pharmaceutical compositions which contain these compounds. These dihydrothienopyrimidinesulphoxides are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system, or cancers.

Heterocycle-substituted piperazino-dihydrothienopyrimidines

A method for treating diseases associated with the inhibition of phosphodiesterase 4 (PDE4) enzyme in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a dihydrothienopyrimidinesulphoxide of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof 

Piperazino-dihydrothienopyrimidine derivatives

There are provided compounds of formula (I), wherein R, R, R, Q, Q, Q, Q, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer. 

1H-benzimidazole-5-carboxamides as anti-inflammatory agents

The present invention relates to compounds of general formula I in which A, L, M, Q, Q, Q, R, R, R, R, R, W, X, Y, Z, Z, Zare defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.

Compounds

1H-benz imidazole-5-carboxamides as anti-inflammatory agents

Piperidinodihydrothienopyrimidines of formula 1 wherein X is SO or SO(preferably SO), and R, R, R, and Rmay have the meanings given in the disclosure and claims, pharmacologically acceptable salts thereof, and pharmaceutical compositions containing these compounds. These piperidinodihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system, or cancers.

Substituted piperazino-dihydrothienopyrimidines

3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents

3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents

The invention relates to the novel dihydrothienopyrimidine sulfoxides of formula (I) and to the pharmacologically acceptable salts thereof, wherein X represents SO or SO, preferably however SO, and wherein R, R, R, R, Rand Rare defined as in claim. The invention also relates to pharmaceutical compositions containing said compounds. The novel dihydrothienopyrimidine sulfoxides are suitable for use in the treatment of respiratory or gastrointestinal disorders or diseases, inflammatory diseases of the joints, the skin or the eyes, diseases of the peripheral or central nervous system or cancers. 

Piperazinodihydrothienopyrimidine derivatives

The present invention relates to substituted amino-benzimidazoles of general formula (1) wherein the groups Rto Rand A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases. 

Substituted amino-benzimidazoles, medicaments comprimising said compound, their use and their method of manufacture

The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups Rto R, A, B, L, i as well as X&#x2014;Xare defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.

Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof

A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid &#x3b2; peptides (A&#x3b2;) and/or with a changed ratio of levels of A&#x3b2; isoforms and/or with the formation of plaques containing amyloid &#x3b2; peptide (A&#x3b2;) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R, R, R, R, L1 and i are defined as in claim

Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds

Method of treating diseases and conditions associated with an altered level of amyloid &#x3b2; peptides and new enolcarboxamide compounds

Growing community of inventors

Oggelshausen, Germany

Klaus Klinder